Skip to main content

Rett In The News

ProQR
January 5, 2024
ProQR, a biotech company in The Netherlands, and RSRT have initiated a collaboration to develop RNA editiing therapeutics for Rett syndrome. RSRT has made an initial $1 million award to ProQR.
Neurogene
January 5, 2024
Key highlights from Neurogene's update include approval to dose patient #3; clearance to initiate a trial in the UK; plans to expand the US trial to more patients and to test a higher dose; expect to share data on US trial in Q4 2024.
EndPointsNews
January 2, 2024
Anavex Life Sciences, a biotech company that has come under fire for trying to spin its clinical trial results, wants to claim partial success on a late-stage trial in kids with Rett syndrome, a rare genetic neurological disorder. However, the biotech’s own ad-hoc analysis says otherwise.
Neurogene
December 19, 2023
Neurogene has announced that their merger with Neoleukin is finalized. The company has sufficient funds to advance their gene therapy programs into the second half of 2026.